These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 20686482)

  • 1. Type IIA topoisomerase inhibition by a new class of antibacterial agents.
    Bax BD; Chan PF; Eggleston DS; Fosberry A; Gentry DR; Gorrec F; Giordano I; Hann MM; Hennessy A; Hibbs M; Huang J; Jones E; Jones J; Brown KK; Lewis CJ; May EW; Saunders MR; Singh O; Spitzfaden CE; Shen C; Shillings A; Theobald AJ; Wohlkonig A; Pearson ND; Gwynn MN
    Nature; 2010 Aug; 466(7309):935-40. PubMed ID: 20686482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.
    Bax BD; Murshudov G; Maxwell A; Germe T
    J Mol Biol; 2019 Aug; 431(18):3427-3449. PubMed ID: 31301408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
    Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
    Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds.
    Kolarič A; Germe T; Hrast M; Stevenson CEM; Lawson DM; Burton NP; Vörös J; Maxwell A; Minovski N; Anderluh M
    Nat Commun; 2021 Jan; 12(1):150. PubMed ID: 33420011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.
    Chan PF; Srikannathasan V; Huang J; Cui H; Fosberry AP; Gu M; Hann MM; Hibbs M; Homes P; Ingraham K; Pizzollo J; Shen C; Shillings AJ; Spitzfaden CE; Tanner R; Theobald AJ; Stavenger RA; Bax BD; Gwynn MN
    Nat Commun; 2015 Dec; 6():10048. PubMed ID: 26640131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.
    Black MT; Stachyra T; Platel D; Girard AM; Claudon M; Bruneau JM; Miossec C
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3339-49. PubMed ID: 18625781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
    Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
    J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.
    Franco-Ulloa S; La Sala G; Miscione GP; De Vivo M
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
    Alt S; Mitchenall LA; Maxwell A; Heide L
    J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
    Tomašič T; Katsamakas S; Hodnik Ž; Ilaš J; Brvar M; Solmajer T; Montalvão S; Tammela P; Banjanac M; Ergović G; Anderluh M; Peterlin Mašič L; Kikelj D
    J Med Chem; 2015 Jul; 58(14):5501-21. PubMed ID: 26098163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.
    Germe T; Vörös J; Jeannot F; Taillier T; Stavenger RA; Bacqué E; Maxwell A; Bax BD
    Nucleic Acids Res; 2018 May; 46(8):4114-4128. PubMed ID: 29538767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
    Gibson EG; Bax B; Chan PF; Osheroff N
    ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
    Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
    Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity.
    Fois B; Skok Ž; Tomašič T; Ilaš J; Zidar N; Zega A; Peterlin Mašič L; Szili P; Draskovits G; Nyerges Á; Pál C; Kikelj D
    ChemMedChem; 2020 Feb; 15(3):265-269. PubMed ID: 31721445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
    Tomašić T; Mašič LP
    Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
    Durcik M; Nyerges Á; Skok Ž; Skledar DG; Trontelj J; Zidar N; Ilaš J; Zega A; Cruz CD; Tammela P; Welin M; Kimbung YR; Focht D; Benek O; Révész T; Draskovits G; Szili PÉ; Daruka L; Pál C; Kikelj D; Mašič LP; Tomašič T
    Eur J Med Chem; 2021 Mar; 213():113200. PubMed ID: 33524686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.